type here...

CATEGORIES

Healthcare

LATEST

1...565758...74Page 57 of 74

TRENDING

EDITORS CHOICE

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

Medika Life -
The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

The Battle Against An Ignoble Death

Dr. Hesham A. Hassaballa -
The battle against critical illness in the ICU is self-evident. The battle against an ignoble death is paramount for me.

Galen Growth FemTech 2.0 Report: Elevating Women’s Health from Niche to Necessity

Gil Bashe, Medika Life Editor -
There’s a truth in health innovation: “Where data meets intent, change follows.” The latest Galen Growth report—FemTech 2.0: Doubling Down on Growth—is not just...

Covid is Never Going to Be Over. We Need to Plan Accordingly

Robert Turner, Founding Editor -
Is SARS-CoV-2 nothing more than aggressive Influenza, a new breed of Flu. It looks that way and it may be here to stay. We need to deal with that.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories